{"entity":{"id":"nct06028074","kind":"trial","name":"Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies","aka":[],"tldr":"A phase 1/2 trial of GIM122 in advanced solid tumours, run by Georgiamune Inc, now recruiting.","summary":"Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT06028074 by Georgiamune Inc, with 111 participants planned, started 2023-12-12 and due to reach its primary completion in 2026-09. Interventions recorded: GIM122.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06028074","url":"https://clinicaltrials.gov/study/NCT06028074"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["georgiamune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06028074","phase":"1/2","setting":"A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation With Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of GIM-122 as a Single Agent in Adult Subjects With Advanced Solid Malignancies","sponsor":"Georgiamune Inc","enrolled":111,"outcomes":[]},"route":"/trials/nct06028074/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"georgiamune","kind":"company","name":"Georgiamune","route":"/companies/georgiamune/"}]}}